

Press release

Lund November 13th, 2018

EQL Pharma AB (publ)

Org.no. 556713-3425



Clindamycin EQL Pharma approved

The drug Clindamycin EQL Pharma, capsules 150mg and 300mg, has been approved for sale by the Swedish Medicines Agency.

Clindamycin EQL Pharma is a bactericidal agent (antibiotic). Clindamycin EQL Pharma is used for the treatment of bacterial infections in the pharynx and in skin and soft tissues.

Clindamycin EQL Pharma contains clindamycin, an antibiotic substance that has been registered in Sweden since 1987. The market for clindamycin capsules is medium sized, with around 17 MSEK in annual sales in Sweden, and a limited numbers of competitors.

The product is expected to be launched in the second quarter, 2019.

For further information, please contact:

Christer Fåhraeus

CEO EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

About EQL Pharma

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets 10 niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (7) people and is listed on Spotlight Stock Market. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.